Cancers involving the oesophagus and the gastro-oesophageal (GE) junction are the eighth most common cancer in the world ([@bib3]). The overall survival (OS) rates for patients with GE cancers remain dismal with survival measured in months.

Blockade of the vascular endothelial growth factor (VEGF) pathway in GE cancer remains a valid therapeutic strategy. There are three known VEGF receptors (VEGFRs): VEGFR-1, -2, and -3 with VEGFR-2 being the main effector of angiogenesis. Patients with oesophageal cancer were found to have significantly higher levels of serum VEGF when compared to controls ([@bib2]). Vascular endothelial growth factor receptor levels correlate with a more aggressive behaviour in GE cancers, likely through promoting paracrine and autocrine pathways involved in tumour metastasis ([@bib20]). Blocking angiogenesis is therefore an attractive strategy to inhibit tumour growth, invasion, and metastasis in GE cancers. Recently, positive results from two randomised clinical trials with ramucirumab (Cyramza--Lilly, Indianapolis, IN, USA), a monoclonal antibody to VEFGR-2, suggest that inhibition of the VEGF pathway remains a valid treatment approach ([@bib4] and [@bib18]).

Sunitinib (Sutent-Pfizer, New York, NY, USA) is a multikinase inhibitor of mainly VEGFR-1, -2, and -3, and PDGFR with documented activity in a variety of tumours ([@bib5]). In preclinical studies, VEGF-A stimulated proliferation of VEGFR-2 expressing gastric cancer cell lines and sunitinib effectively inhibits cell growth in a dose-dependent manner [@bib7]). Xenograft tumours in mice treated with sunitinib were found to have decrease in tumour volume and Ki67-staining cells ([@bib21]). Thus, we hypothesised that sunitinib would be active in patients with GE cancers. For our exploratory correlative studies, we analysed serial serum levels of VEGF-A--D, VEGFR-2 and -3, and placenta growth factor (PlGF) to determine whether their levels correlated with prognosis or were predictive of therapy benefit. Tumour gene expression profiling was performed to identify differential gene expressions in patients who did *vs* who did not benefit from sunitinib. In addition, dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) was performed to assess the acute effects of sunitinib on tumour vascularity and viability. Herein, we present the results of a phase II study of sunitinib in patients with relapsed/refractory with oesophageal and GE cancers.

Patients and Methods
====================

Eligibility
-----------

Patients were required to have unresectable pathologically confirmed oesophageal or GE cancer, measurable disease per RECIST 1.0, no \>2 lines of prior palliative therapy, no prior anti-VEGF therapy, ECOG performance status of ⩽1, no cardiac dysrhythmias, normal or well-controlled blood pressure, normal or well-controlled thyroid function, and no warfarin.

Study design
------------

This phase II study protocol was approved by the institutional review board at The Ohio State University, and the registered trial number is NCT00702884. Informed consent was obtained from each patient. The primary end point was to assess PFS rate at 24 weeks. The secondary end points included overall response rate, median OS, and toxicities. Correlative end points assessed tumour transcriptome expression, changes in vascularity via DCE-MRI, and serum angiogenesis markers.

Sunitinib administration and dose modification
----------------------------------------------

Patients received sunitinib 37.5 mg by mouth daily, with two planned dose-reduction levels (25 and 12.5 mg).

Assessment of response and toxicity
-----------------------------------

Tumours measurements were assessed by CT scans every 6 weeks according to RECIST criteria ([@bib15]). Toxicities were graded according to the NCI Common Toxicity Criteria version 3.0 (<http://ctep.cancer.gov/protocolDevelopment/electronic_applications/docs/ctcaev3.pdf>).

Serum molecular correlates
--------------------------

Blood samples were collected before starting sunitinib at weeks 2 and 6 of treatment, and after disease progression. Commercial ELISA kits were utilised for serum measurement of VEGF (A, C, and D), VEGFR (2 and 3), and PlGF.

Tumour gene expression analysis
-------------------------------

Total RNA was extracted from tumour samples using the Norgen Biotek FFPE RNA purification kit. Whole-transcriptome profiling was performed using the SensationPlus FFPE kit and Affymetrix HTA 2.0 array. Exon-level normalisation was performed followed by gene-level summarisation.

Advanced imaging
----------------

Longitudinal DCE-MRI studies were performed at weeks 0, 2, 6, and 12 to track changes in tumour volume, perfusion, and vascular permeability. Magnetic resonance imaging studies were performed with a 3-Tesla scanner (Achieva; Philips Healthcare, Cleveland, OH, USA) using a 16- or 32-channel phased-array coil and multi-transmit. The DCE-MRI data acquired in the axial and coronal planes were analysed with specialised software written in IDL (Exelis, Boulder, Co., Boulder, CO, USA). Pharmacokinetic analysis was performed on the tracer kinetic curves derived from manually traced, motion-compensated regions of interest using the adjusted Brix\'s model ([@bib19]).

Statistical methods
-------------------

This study was a single-stage Fleming phase II study with 25 patients. If 5 ⩾ patients were progression free at 24 weeks, sunitinib would be recommended for further investigation (*a*=0.10, *b*=0.10; *P*~0~=0.10, *P*~1~=0.30). The historical control is from a phase II study of gefitinib in second-line therapy of advanced oesophageal cancer, and results showed that of the 26 patients evaluated, treatment was \>8 weeks in 15 out of 26 patients (58% [@bib17]). Thus, time to progression would be 10 weeks or 17% progression free at 24 weeks. Survival curves were estimated using the Kaplan--Meier method, and 95% confidence intervals (CI) for the medians are provided. Log-rank test was used to compare PFS between the patients with clinical benefit (non-progressors) *vs* disease progression. Secondary end points were evaluated using descriptive statistics. Linear mixed effect model was used to examine the correlation between clinical benefit and serum levels for VEGF (A, C, and D), PIGF, and VEGFR (2 and 3) through time (baseline, 2 weeks, 6 weeks, and 12 weeks). Dynamic contrast-enhanced magnetic resonance imaging pharmacokinetic parameters and RECIST size measurements were studied through time using linear mixed effect models. For tumour gene expression analysis, paired *t*-test analysis was performed based on desired response parameters to generate a nominal *P*-value.

Results
=======

Patient characteristics
-----------------------

Twenty-five evaluable patients were enrolled and evaluable for toxicities ([Table 1](#tbl1){ref-type="table"}). Twenty-four patients were evaluable for response. All patients were evaluable for OS and PFS.

Treatment toxicity
------------------

Most common grade 3 toxicities included fatigue (24%), anaemia (20%), and leucopenia (16%) ([Table 2](#tbl2){ref-type="table"}). There were no grade 4 non-haematological toxicities. Dose reductions were necessary for three patients due to grade 2 pain, grade 3 thrombocytopenia, and grade 3 anaemia. No patients came off of study due to toxicities.

Treatment efficacy
------------------

Progression-free survival at 24 weeks was 8% (two patients; 95% CI: 1.4--22.5%) ([Table 3](#tbl3){ref-type="table"} and [Figure 1](#fig1){ref-type="fig"}). Three patients had partial response (PR), and their duration of best response was 16, 23, and 72 weeks. The patient who had PR for 16 weeks initially presented with a T1 oesophageal adenocarcinoma that was surgically resected, but then developed local recurrence with metastatic lymph node and omental disease 6 months after his surgery. He received sunitinib as first-line therapy. The second patient with PR for 23 weeks was diagnosed with metastatic squamous cell oesophageal cancer with widely metastatic nodal disease in the chest and abdomen, and sunitinib was also her first-line therapy. The final patient presented with metastatic GE adenocarcinoma with liver involvement. He was initially treated on a clinical trial with FOLFOX and vismodegib, and then treated with sunitinib as second-line therapy. Nine patients had stable disease (SD), including seven with SD lasting \>10 weeks. Most patients with SD had relative shrinkage or no growth of their target lesions ([Figure 1](#fig1){ref-type="fig"}).

Correlative studies
-------------------

### Serum marker analysis

Correlation between baseline VEGF-A and -C levels and treatment response: Serum levels for VEGF (A, C, and D), PIGF, and VEGFR (2 and 3) were obtained in 24 patients ([Figure 2](#fig2){ref-type="fig"} and [Supplementary Table 1](#sup1){ref-type="supplementary-material"}). Patients who had clinical benefit had higher VEGF-C baseline values (*P*=0.04). In addition, VEGF-C levels were decreased at 2 weeks (*P*=0.03) and 6 weeks (*P*=0.01). Conversely, patients with PD were observed to have an increase in serum VEGF-A levels at weeks 2 and 6 (*P*=0.02 for both time points). Patients with PD had an increase in serum levels of PlGF from baseline to 2 weeks (*P*=0.0003) and a trend for continued increase at week 6. VEGFR-2 was decreased at weeks 2 and 6 in both groups.

### Gene transcriptome profile

Correlation between gene expression profiling and clinical benefit: Sixteen formalin-fixed, paraffin-embedded biopsy of tumours from 15 patients were obtained from patients before starting sunitinib therapy were evaluable for gene expression profiling ([Figure 3](#fig3){ref-type="fig"} and [Supplementary Table 2](#sup1){ref-type="supplementary-material"}). There were 44 699 gene transcript clusters evaluated between the six patients who derived clinical benefit and nine who had PD. There were 47 differentially expressed transcript clusters in coding regions (nominal *P*⩽0.05). A nominal *P*-value was chosen given that this was exploratory in nature. There were 12 transcript clusters that mapped to known genes. Seven of these 12 transcript clusters corresponded to complement factor B (CFB) with a median fold-change of 1.71. A significant trend for increased CFB expression was found in the six patients who had clinical benefit with improved PFS but not OS ([Supplementary Table 2](#sup1){ref-type="supplementary-material"}).

Advanced Imaging results
------------------------

Dynamic contrast-enhanced magnetic resonance imaging pharmacokinetic parameters and RECIST size measurements were analysed in 16 patients ([Supplementary Figure 1](#sup1){ref-type="supplementary-material"}). The difference in baseline mean tumour size and the MRI parameters were not significantly different between the two patient groups: (patients with PD patients with clinical benefit) tumour size 6.77 cm (*P*=*0.79*), Amp 0.56 (*P*=0.22), *K*~ep~ 1.53 min^−1^ (*P*=0.18), *K*~pe~ −0.04 min^−1^ (*P*=*0.97*), and *K*~el~ 0.02 min^−1^ (*P*=*0.50*). Patients with clinical benefit had stable mean tumour size over the initial 12 weeks, suggesting a cytostatic response to sunitinib. This is supported by the flat trend observed in the Amp values that indicate sunitinib did not induce any substantial change in tumour perfusion. The plasma-to-extracellular space transfer rate *K*~pe~ shows a decrease at week 2 in patients with clinical benefit, although this is not statistically significant (*P*=0.14), likely a result of sunitinib-induced normalisation of tumour microvasculature.

Discussion
==========

Patients with oesophageal and GE cancers have poor outcomes. Despite some early disappointments with targeting the VEGF pathway with bevacizumab (Avastin--Roche/Genentech, San Francisco, CA, USA), a monoclonal antibody blocking VEGF-A ligand, recent trials with ramicurumab in patients with refractory gastric cancer showed an improvement in outcome ([@bib14], [@bib4], [@bib18], and [@bib9]). Another recent study suggested a significant benefit in gastric cancer with apatinib, a multikinase inhibitor similar to sunitinib *vs* best supportive care ([@bib10]).

There have been no reported prior studies of single-agent sunitinib in oesophageal and GE cancers, although sunitinib has been given in combination with chemotherapy with no improved PFS. A phase II study from the Hoosier Oncology Group treated 28 patients with advanced oesophageal cancer with the combination of sunitinib (37.5 mg orally daily) and paclitaxel (90 mg m^−2^ intravenously on days 1, 8, and 15 of a 28-day cycle). Results showed that PFS at 24 weeks was 25% (90% CI: 12--42%), which was not improved from historical control ([@bib12]). In addition, a randomised placebo-controlled phase II study of FOLFIRI with or without sunitinib in 91 patients with advanced GE cancers showed that median PFS was similar in the sunitinib *vs* placebo arm (3.6 *vs* 3.3 months, respectively, HR 1.11, 95% CI: 0.70--1.74, *P*=0.66; [@bib8]).

Sunitinib was well tolerated at a daily oral dose of 37.5 mg, no one came off of trial due to toxicities. Although our study did not achieve its primary end point, the presence of objective durable responses in three patients is encouraging. The overall outcome in our study is comparable to other studies in gastric and GE cancer ([@bib4] and [@bib18])

Our correlative studies were performed to identify potential prognostic or predictive biomarkers. The DCE-MRI data support that patients who derived clinical benefit from sunitinib had a decrease in tissue perfusion. VEGR-2 and -3 serum levels were decreased from baseline in all patients at weeks 2 and 6 of treatment. This likely reflects drug inhibition and may not necessarily correspond with disease response ([@bib6]).

Placenta growth factor, a ligand for VEGFR-1, had a significant increase at week 2 in patients who had PD. However, there was a trend for increase in PlGF over time in all patients, which could be due to inhibition of VEGFR. In the AVAGAST trial, high baseline plasma levels of VEGF-A were suggested to be predictive of sensitivity to bevacizumab in Western patients ([@bib16]). In our study, we noticed that the trend of stable VEGF-A levels rather than the baseline level was indicative of treatment response. Patients with PD had an increase in their VEGF-A levels at weeks 2 and 6 of treatment. In contrast, patients who had clinical benefit did not have an increase in subsequent VEGF-A levels. Interestingly, patients who had clinical benefit had higher levels of serum VEGF-C at baseline and a significant decrease in serum levels at weeks 2 and 6 of therapy. A similar finding with sunitinib was documented in renal cell carcinoma but only with baseline VEGF-C levels ([@bib11]). As such, our findings with serum VEGF-A and -C levels may be early predictor of clinical benefit of VEGF-directed therapy.

Tumour transcriptome analysis revealed that differential CFB expression was observed in patients who derived clinical benefit from sunitinib *vs* those with PD. CFB circulates in the blood and is involved in the normal activation of the alternative complement pathway. It is cleaved by complement D to yield two subunits, Ba and Bb, which are involved in the proliferation of B lymphocytes. CFB has been found to be important for driving inflammation and angiogenesis via secretion of VEGF. CFB has been studied in the pathogenesis of age-related macular degeneration (AMD), a disease that is typically treated with anti-angiogenic agents such as aflibercept and bevacizumab ([@bib13]). In mouse models for AMD, laser treatment to the Bruch\'s membrane, the innermost layer of the choroid in the eye, showed increase production of angiogenic factors. However, mice treated with siRNA to CFB had low levels of VEGF and TGF-B2 after laser treatment, demonstrating the significance of CFB in the angiogenesis pathway ([@bib1]). Based on our results, we hypothesise that sunitinib may block CFB or inflammation-dependent VEGF release in GE tumours. Elevated CFB transcript levels may predict for response to sunitinib and other VEGF-directed therapy.

In conclusion, sunitinib is well tolerated but seems to benefit only a subgroup of patients. It is important to identify a biomarker that will predict response to therapy, and our correlative studies have found possible candidates although further validation is needed. Changes in baseline serum levels of VEGF-A and -C may serve as early predictors of clinical benefit with significant potential implications for the design of future trials. More interestingly, our study includes the first report of differential CFB expression as a potential predictor for efficacy of anti-angiogenic therapy in a solid tumour, and may warrant further investigation in future trials with anti-VEGF drugs.
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![Waterfall plot of patients\' best response.](bjc2015197f1){#fig1}

![Serum growth factor levels. Patients who had PD are in red and patients who had clinical benefit (SD or PR) are in black. Patients with PD were found to have significantly higher VEGF-A levels at week 2, as compared with baseline. Patients who did derive clinical benefit from sunitinib were found to have statistically significant higher VEGF-C levels at baseline, and decrease at 2 weeks.](bjc2015197f2){#fig2}

![Heat map of CFB gene isoform expression levels. Patients who did not have disease progression (SD+PR) are depicted in orange, whereas those with PD are in green. Expression levels red=high, blue=low. Collectively, there was a statistical trend towards higher expression of CFB in those patients who benefited from VEGFR inhibition.](bjc2015197f3){#fig3}

###### Patient characteristics

  **Characteristics**                       ***N*** **(%)**
  ---------------------------------------- -----------------
  Median age (range, years)                   61 (38--74)
  **Sex**                                  
  Male                                          22 (88)
  Female                                        3 (12)
  **Race**                                 
  White                                         23 (92)
  Black                                          2 (8)
  **ECOG**                                 
  0                                             9 (36)
  1                                             16 (64)
  **Disease site**                         
  Oesophagus                                    15 (60)
  Gastro-oesophageal junction                   10 (40)
  **Tumour histology**                     
  Adenocarcinoma                                24 (96)
  Squamous cell                                  1 (4)
  **Number of metastatic site**            
  1                                             10 (40)
  2                                             10 (40)
  3                                             5 (20)
  **Prior lines of therapy**               
  0                                              2 (8)
  1                                             19 (76)
  2                                             3 (12)
  3                                              1 (4)
  **Prior surgery with curative intent**        10 (40)
  **Prior chemoradiation therapy**              15 (60)
  Neoadjuvant intent                            8 (32)
  Definitive intent                             4 (16)
  Adjuvant intent                                2 (8)
  Palliative intent                              1 (4)
  **Prior systemic chemotherapy**               13 (52)
  Cisplatin/irinotecan                           2 (8)
  Carboplatin/paclitaxel                         2 (8)
  Carboplatin/paclitaxel/capecitabine           3 (12)
  5-FU/oxaliplatin                              3 (12)
  Epirubicin/cisplatin/5-FU                      1 (4)
  Capecitabine/irinotecan                        1 (4)
  Cisplatin/5-FU                                 1 (4)

Abbreviations: ECOG=Eastern Cooperative Oncology Group; 5-FU=5-fluorouracil.

###### Related toxicities

                            **Grade 1/2** ***N*** **(%)**   **Grade 3** ***N*** **(%)**   **Grade 4** ***N*** **(%)**
  ------------------------ ------------------------------- ----------------------------- -----------------------------
  **Haematological**                                                                     
  Leukopenia                           8 (32)                         3 (12)                         1 (4)
  Lymphopenia                          4 (16)                         3 (12)                           0
  Neutropenia                          6 (24)                          2 (8)                         1 (4)
  Anaemia                              12 (48)                        3 (12)                         2 (8)
  Thrombocytopenia                      3(12)                         3 (12)                         1 (4)
  **Non-haematological**                                                                 
  Anorexia                             12 (48)                           0                             0
  Diarrhoea                            11 (44)                           0                             0
  Fatigue                              13 (52)                        6 (24)                           0
  Mucositis                            7 (28)                            0                             0
  Hypertension                          2 (8)                          1 (4)                           0
  Haemorrhage                          6 (24)                          1 (4)                           0
  Hyperglycaemia                       6 (24)                          2 (8)                           0
  Abdominal pain                       10 (40)                         2 (8)                           0
  Nausea                               13 (52)                         1 (4)                           0
  Vomiting                             9 (36)                            0                             0

###### Efficacy results

  **End point**             ***N*** **(%)**   **95% CI**
  ------------------------ ----------------- ------------
  PFS at 24 weeks                2 (8)        1.4--22.5%
  Median PFS (weeks)              6.9         5.6--11.4
  Median OS (weeks)              16.6         8.9--25.3
  **ORR**                                    
  PR                           3 (12.5)            
  SD                           9 (37.5)            
  SD \>10 weeks                 7 (29)             
  DCR (PR+SD \>10 weeks)        10 (42)            
  PD                            12 (50)            

Abbreviations: CI=confidence interval; ORR=overall response rate; OS=overall survival; PFS=progression-free survival; PR=partial response; SD=stable disease.
